MYO reagent (chemiluminescence assay)

Methodology                                                                                 

Chemiluminescence immunoassay

MYO                                                                                                 

1.Early sensitive indicator of myocardial infarction

2.Good indicator of re-infarction

Clinical Significance                                                                  

Began to rise after 1-2hrs

Reach peak value after 4-8hrs  

Return to normal value after20-36 hrs

The most important indicator of AMI early negative elimination

AMI recurrence detection, most sensitive indicators of reperfusion therapy testing.

50% Cardiovascular mortality

Product advantage

High sensitivity: 5ng/ml

High accuracy: 99% result correlation with similar product of Siemens ADVIA Centaur

Wide linear range: 5 -1000ng/ml

Performance analysis                                                               

Correlation between Norman MYO and Siemens ADVIA Centaur MYO

Technical parameters

Methodology: chemiluminescence

Linear range:5-1000ng/ml

Sensitivity:≤5ng/ml

Test sample: serum, whole blood

reference value:≤70ng/ml

Reagent stability  :12 months period of validity of Main reagent, 37℃heat failure treatment,

Stable within 7 days, decline iswithin 10%.

Company Profile                                                                         

Nanjing Norman Biological Technology Co., Ltd is dedicated to R&D and manufacturing of

 automated chemiluminescence system. Founded in 2008, Norman biological has been 

upholding the idea that R&D shapes future ,and concentration determines success. Ever

 since the beginning,Norman has been focusing on developing and manufacturing 

chemiluminescence and immunofluorescence  reagents.

Norman's manufacture center is located in the Yuhua District and owns an over 2,000m2

GMP-approved clean workshop. The R&D base, which is over 2,000m2 , is located in state-

level new Jiangbei district. Now there are over 100 R&D engineers, 40% of which hold a 

PhD or master's degree.

Powered by advanced technology and excellent talents in the IVD field, Norman has 

been consistently improving its innovation platform , and increasing R&D investment. 

Self-innovation, combined with long-term strategic cooperation with universities and

research institutes and with outsourced technologies, ensures consistent improvement 

on product quality. Norman's R&D field has covered instruments, reagents, and raw 

materials, and has been entrusted by the Nanjing government to build a R&D center 

specialized in biological chemistry and immunity diagnosis. Up to now, Norman has 

acquired over 20 patents.

Being an expert in automated chemiluminescence analysis , Norman owns independent 

and completed intellectual property rights, and its products provide top-notch sensitivity, 

precision and accuracy . Thanks to the self-developed antigens and self-manufactured 

antibodies, Norman's products features minimized intra-and inter- batch difference.

After 8 years development, Norman is now on the fast track. An over 30,000m2 global 

R&D center is in construction, and will hold more than 1,000 R&D engineers in the future.

R&D shapes future, and concentration determines success. Driven by the commitment to 

"provide complete solution to improve human health", Norman will consistently do its 

utmost to drive the IVD industry forward and contribute more to human health.

Agent Wanted                                                                              

If you are interested in working with us, please feel free to contact.

Why us                                                                                            

Manufacturer and Exporter for nearly 10 years with self R&D Research Center;

Professional After-Sale service with On-site support worldwide; 

CE/ISO13485 Certifications

OEM and ODM are available !